Literature DB >> 9890856

Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial.

J L Lin1, H H Ho, C C Yu.   

Abstract

BACKGROUND: Nephropathy is known to occur in persons exposed to high levels of lead, but the question of whether long-term exposure to low levels of environmental lead is associated with impaired renal function remains controversial.
OBJECTIVE: To examine whether chelation therapy slows the progression of renal insufficiency in patients with mildly elevated body lead burden.
DESIGN: Randomized, controlled trial.
SETTING: Academic medical center in Taiwan. PATIENTS: 32 patients with chronic renal insufficiency (serum creatinine level > 132.6 micromol/L [1.5 mg/dL] and < 353.8 micromol/L [4.0 mg/dL]), mildly elevated body lead burden (> 0.72 micromol [150 microg] of lead per 72-hour urine collection and < 2.90 micromol [600 microg] of lead per 72-hour urine collection [EDTA mobilization tests]), and no history of heavy lead exposure. INTERVENTION: The treatment group received 2 months of chelation therapy; the control group received no therapy. MEASUREMENTS: The reciprocal of serum creatinine (1/Cr) was used as an index of progressive renal insufficiency.
RESULTS: Rates of progression of renal insufficiency were similar in the treatment group and the control group during a 12-month baseline observation period (1/Cr, 0.000054 L/micromol per month compared with 0.000046 L/micromol per month; P > 0.2). After the 2-month treatment period, improvement in renal function was greater in the treatment group than in the control group. In the 12 months after the treatment period, renal insufficiency progressed more slowly in the treatment group than in the control group (1/Cr, 0.000033 +/- 0.00038 L/micromol per month compared with 0.000045 +/- 0.000038 L/micromol per month; P = 0.0030).
CONCLUSION: Chelation therapy seems to slow the progression of renal insufficiency in patients with mildly elevated body lead burden. This implies that long-term exposure to low levels of environmental lead may be associated with impaired renal function in patients with chronic renal disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9890856     DOI: 10.7326/0003-4819-130-1-199901050-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  How well is the clinical importance of study results reported? An assessment of randomized controlled trials.

Authors:  K B Chan; M Man-Son-Hing; F J Molnar; A Laupacis
Journal:  CMAJ       Date:  2001-10-30       Impact factor: 8.262

Review 2.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

3.  Associations of lead biomarkers with renal function in Korean lead workers.

Authors:  V M Weaver; B-K Lee; K-D Ahn; G-S Lee; A C Todd; W F Stewart; J Wen; D J Simon; P J Parsons; B S Schwartz
Journal:  Occup Environ Med       Date:  2003-08       Impact factor: 4.402

4.  Do people from Taiwan have higher heavy metal levels than those from Western countries?

Authors:  Ta-Yuan Liu; Yao-Min Hung; Wei-Chun Huang; Ming-Ling Wu; Shoa-Lin Lin
Journal:  Singapore Med J       Date:  2016-04-19       Impact factor: 1.858

Review 5.  An update on 'progression promoters' in renal diseases.

Authors:  C O Alebiosu
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

Review 6.  Chelation in metal intoxication.

Authors:  Swaran J S Flora; Vidhu Pachauri
Journal:  Int J Environ Res Public Health       Date:  2010-06-28       Impact factor: 3.390

7.  Scientific publications in nephrology and urology journals from Chinese authors in East Asia: a 10-year survey of the literature.

Authors:  Jing Xu; Zhi-Guo Mao; Mei Kong; Liang-Hao Hu; Chao-Yang Ye; Cheng-Gang Xu; Shu Rong; Li-Jun Sun; Jun Wu; Bing Dai; Dong-Ping Chen; Yu-Xian Zhu; Yi-Xiang Zhang; Yu-Qiang Zhang; Xue-Zhi Zhao; Chang-Lin Mei
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

8.  Associations of uric acid with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers.

Authors:  Virginia M Weaver; Brian S Schwartz; Bernard G Jaar; Kyu-Dong Ahn; Andrew C Todd; Sung-Soo Lee; Karl T Kelsey; Ellen K Silbergeld; Mark E Lustberg; Patrick J Parsons; Jiayu Wen; Byung-Kook Lee
Journal:  Environ Health Perspect       Date:  2005-11       Impact factor: 9.031

9.  Protective effect of EDTA preadministration on renal ischemia.

Authors:  Chiara Foglieni; Alessandro Fulgenzi; Paolo Ticozzi; Fabio Pellegatta; Clara Sciorati; Daniela Belloni; Elisabetta Ferrero; Maria Elena Ferrero
Journal:  BMC Nephrol       Date:  2006-03-15       Impact factor: 2.388

10.  The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.

Authors:  John W Baynes; David B Murray
Journal:  Exp Diabetes Res       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.